OncoMatch/Clinical Trials/NCT03907475
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Is NCT03907475 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for locally advanced malignant solid neoplasm.
Treatment: Capecitabine · Carboplatin · Durvalumab · Gemcitabine Hydrochloride · Nab-paclitaxel · Paclitaxel · Pegylated Liposomal Doxorubicin Hydrochloride — This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, capecitabine, carboplatin, paclitaxel, and nab-paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with durvalumab may improve how immune cells respond and attack tumor cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage III, IV
metastatic or locally advanced (not amenable to surgery) solid tumors
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: checkpoint inhibitor
Exception: patients who had prior ctla-4 inhibitor treatment and did not experience serious adverse events are eligible for all arms. patients who had prior pd-l1/pd-1 inhibitor treatment and did not experience serious adverse events are excluded from the durvalumab monotherapy arm but are eligible for the chemotherapy combinations.
Lab requirements
Blood counts
Absolute neutrophil count >= 1,000/uL; Platelets >= 100,000/uL
Kidney function
Calculated creatinine clearance > 40 mL/min by Cockcroft-Gault formula
Liver function
Total bilirubin < 1.5 x institutional upper limit of normal (Gilbert syndrome exception at PI discretion); AST/ALT <= 3 x ULN, or up to 5 x ULN if liver metastases are present
Cardiac function
Left ventricular ejection fraction greater than 50% or institutional lower limit of normal by echocardiography (ECHO) at entry (patients enrolling on Arm 3 only)
Absolute neutrophil count >= 1,000/uL (mcL). Platelets >= 100,000/uL (mcL). Total bilirubin < 1.5 x institutional upper limit of normal. AST/ALT <= 3 x ULN, or up to 5 x ULN if liver metastases are present. Calculated creatinine clearance > 40 mL/min by Cockcroft-Gault formula. Left ventricular ejection fraction greater than 50% or institutional lower limit of normal by echocardiography (ECHO) at entry (patients enrolling on Arm 3 only).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Cancer Institute Developmental Therapeutics Clinic · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify